《MMWR,3月6日,Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 — United States, January–February 2020》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-03-07
  • Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 — United States, January–February 2020

    Weekly / March 6, 2020 / 69(9);245–246

    On March 3, 2020, this report was posted online as an MMWR Early Release.

    Rachel M. Burke, PhD1; Claire M. Midgley, PhD1; Alissa Dratch, MPH2; Marty Fenstersheib, MD; Thomas Haupt, MS4; Michelle Holshue, MPH5,6; Isaac Ghinai, MBBS6,7; M. Claire Jarashow, PhD8; Jennifer Lo, MD9; Tristan D. McPherson, MD6,10; Sara Rudman, MD; Sarah Scott, MD6,12; Aron J. Hall, DVM1; Alicia M. Fry, MD1; Melissa A. Rolfes, PhD1 (View author affiliations)

    In December 2019, an outbreak of coronavirus disease 2019 (COVID-19), caused by the virus SARS-CoV-2, began in Wuhan, China (1). The disease spread widely in China, and, as of February 26, 2020, COVID-19 cases had been identified in 36 other countries and territories, including the United States. Person-to-person transmission has been widely documented, and a limited number of countries have reported sustained person-to-person spread.* On January 20, state and local health departments in the United States, in collaboration with teams deployed from CDC, began identifying and monitoring all persons considered to have had close contact† with patients with confirmed COVID-19 (2). The aims of these efforts were to ensure rapid evaluation and care of patients, limit further transmission, and better understand risk factors for transmission.

  • 原文来源:https://www.cdc.gov/mmwr/volumes/69/wr/mm6909e1.htm?s_cid=mm6909e1_w
相关报告
  • 《MMWR,3月13日,Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore — January 2–February 29, 2020》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-03-15
    • Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore — January 2–February 29, 2020 Early Release / March 13, 2020 / 69 Yixiang Ng, MSc1*; Zongbin Li, MBBS1*; Yi Xian Chua, MSc1; Wei Liang Chaw, MSc1; Zheng Zhao, MSc1; Benjamin Er, MSc1; Rachael Pung, MSc1; Calvin J. Chiew, MPH1; David C. Lye, MBBS2,3,4,5; Derrick Heng, MPH1; Vernon J. Lee, PhD1,6* (View author affiliations) Summary What is already known about this topic? First detected in China in late 2019, coronavirus disease 2019 (COVID-19) transmission has spread globally. What is added by this report? Singapore implemented a multipronged surveillance and containment strategy that contributed to enhanced case ascertainment and slowing of the outbreak. Based on review of the first 100 cases, the mean interval from symptom onset to isolation was 5.6 days and declined after approximately 1 month.
  • 《CDC,2月14日,Persons Evaluated for 2019 Novel Coronavirus — United States, January 2020》

    • 来源专题:COVID-19科研动态监测
    • 编译者:xuwenwhlib
    • 发布时间:2020-02-14
    • Persons Evaluated for 2019 Novel Coronavirus — United States, January 2020 Weekly / February 14, 2020 / 69(6);166–170 On February 7, 2020, this report was posted online as an MMWR Early Release. Kristina L. Bajema, MD1,2; Alexandra M. Oster, MD3; Olivia L. McGovern, PhD1,2; Stephen Lindstrom, PhD4; Mark R. Stenger, MA5; Tara C. Anderson, DVM, PhD6; Cheryl Isenhour,, DVM2; Kevin R. Clarke, MD7; Mary E. Evans, MD8; Victoria T. Chu, MD1,4; Holly M. Biggs, MD4; Hannah L. Kirking, MD4; Susan I. Gerber, MD4; Aron J. Hall, DVM4; Alicia M. Fry, MD9; Sara E. Oliver, MD2; 2019-nCoV Persons Under Investigation In December 2019, a cluster of cases of pneumonia emerged in Wuhan City in central China’s Hubei Province. Genetic sequencing of isolates obtained from patients with pneumonia identified a novel coronavirus (2019-nCoV) as the etiology (1). As of February 4, 2020, approximately 20,000 confirmed cases had been identified in China and an additional 159 confirmed cases in 23 other countries, including 11 in the United States (2,3). On January 17, CDC and the U.S. Department of Homeland Security’s Customs and Border Protection began health screenings at U.S. airports to identify ill travelers returning from Wuhan City (4). CDC activated its Emergency Operations Center on January 21 and formalized a process for inquiries regarding persons suspected of having 2019-nCoV infection (2). As of January 31, 2020, CDC had responded to clinical inquiries from public health officials and health care providers to assist in evaluating approximately 650 persons thought to be at risk for 2019-nCoV infection. Guided by CDC criteria for the evaluation of persons under investigation (PUIs) (5), 210 symptomatic persons were tested for 2019-nCoV; among these persons, 148 (70%) had travel-related risk only, 42 (20%) had close contact with an ill laboratory-confirmed 2019-nCoV patient or PUI, and 18 (9%) had both travel- and contact-related risks. Eleven of these persons had laboratory-confirmed 2019-nCoV infection. Recognizing persons at risk for 2019-nCoV is critical to identifying cases and preventing further transmission. Health care providers should remain vigilant and adhere to recommended infection prevention and control practices when evaluating patients for possible 2019-nCoV infection (6). Providers should consult with their local and state health departments when assessing not only ill travelers from 2019-nCoV-affected countries but also ill persons who have been in close contact with patients with laboratory-confirmed 2019-nCoV infection in the United States.